The new SPAC intends to focus on companies in the biotechnology space and will be led by Aaron I. Davis as Chairman and CEO, with Christopher Fuglesang, Ph.D., J.D. serving as President and Director. Michael Beauchamp will also serve as CFO and Treasurer while Andrew Ellis, M.D., J.D. serves as COO and Secretary.
Total SPAC deal count for 2020 year-to-date is now 84 with $33.9 billion in gross proceeds raised. The offering is anticipated to close on Tuesday, September 8, 2020.
SVB Leerink is serving as the sole book runner for the offering. Loeb & Loeb LLP and Kirkland & Ellis, were Issuer’s Counsel and Underwriter’s Counsel, respectively. WithumSmith+Brown, PC, acted as auditor. Continental Stock Transfer & Trust Company is acting as trustee.